INS and diabetic kidney disease: This is a notable contrast to the only study encompassing subjects with DKD, as a dose escalation in the insulin detemir (from 0.2 U to 2.0 U) and in the semaglutide (from 0.25 mg to 0.5 mg) groups was noted (25).